These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30373998)

  • 21. Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report.
    Quiroga García V; Cirauqui Cirauqui B; Tobey Robaina L; López Sisamon D; Hardy-Werbin M; Blanca AB; Margelí Vila M
    Anticancer Drugs; 2016 Jun; 27(5):464-9. PubMed ID: 26813866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Hypercalcemia of Malignancy.
    Chakhtoura M; El-Hajj Fuleihan G
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study.
    Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kim JH; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
    BioDrugs; 2022 May; 36(3):381-392. PubMed ID: 35412221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
    Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
    Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of bone metastases in prostate cancer: a review.
    Bienz M; Saad F
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
    Lehmann T; Aeberli D
    Osteoporos Int; 2017 Oct; 28(10):3067-3068. PubMed ID: 28589418
    [No Abstract]   [Full Text] [Related]  

  • 28. Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
    Iizumi S; Shimoi T; Nishikawa T; Kitano A; Sasada S; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    Intern Med; 2017 Nov; 56(21):2879-2882. PubMed ID: 28943574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic approaches for protecting bone health in patients with breast cancer.
    Lüftner D; Niepel D; Steger GG
    Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse events associated with bone-directed therapies in patients with cancer.
    Jara MA; Varghese J; Hu MI
    Bone; 2022 May; 158():115901. PubMed ID: 33631354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
    Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
    Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-life use of denosumab 120 mg every 12 weeks in prolonged treatment over 2 years of patients with breast cancer bone metastases.
    Irelli A; Sirufo MM; D'Ugo C; Ginaldi L; De Martinis M
    J BUON; 2020; 25(4):1799-1804. PubMed ID: 33099916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
    Stopeck AT; Fizazi K; Body JJ; Brown JE; Carducci M; Diel I; Fujiwara Y; Martín M; Paterson A; Tonkin K; Shore N; Sieber P; Kueppers F; Karsh L; Yardley D; Wang H; Maniar T; Arellano J; Braun A
    Support Care Cancer; 2016 Jan; 24(1):447-455. PubMed ID: 26335402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
    Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
    J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
    Martin M; Bell R; Bourgeois H; Brufsky A; Diel I; Eniu A; Fallowfield L; Fujiwara Y; Jassem J; Paterson AH; Ritchie D; Steger GG; Stopeck A; Vogel C; Fan M; Jiang Q; Chung K; Dansey R; Braun A
    Clin Cancer Res; 2012 Sep; 18(17):4841-9. PubMed ID: 22893628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical femoral fracture associated with bone-modifying agent for bone metastasis of breast cancer: A report of two cases.
    Tateiwa D; Outani H; Iwasa S; Imura Y; Tanaka T; Oshima K; Naka N; Araki N
    J Orthop Surg (Hong Kong); 2017; 25(3):2309499017727916. PubMed ID: 28844196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting bone metastases in prostate cancer: improving clinical outcome.
    Body JJ; Casimiro S; Costa L
    Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.